# CVRx enrols first patient in BENEFIT-HF, a 2,500-patient trial of Barostim in a wider heart failure population

Canonical page: https://technooptimist.io/stories/cvrx-enrols-first-patient-in-benefit-hf-a-2-500-patient-trial-of-b4fa2120
Date: 4 May 2026
About: [CVRx](https://technooptimist.io/companies/cvrx.md) · [Barostim](https://technooptimist.io/neurotech/barostim.md)
Original source: https://citoday.com/news/cvrx-commences-benefit-hf-of-barostim-in-an-expanded-population-of-heart-failure-patients

The first BENEFIT-HF patient was enrolled at North Central Heart in Sioux Falls, South Dakota. The randomised controlled trial will measure all-cause death and heart failure decompensation in a much broader group of patients than Barostim's current label.

## Key facts

- 2,500 patients at about 150 centres in the US and Germany
- CMS approved Category B IDE coverage for trial patients
- Registered as NCT07232030

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.